PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
Protagenic Therapeutics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”) on July 23, 2018. Holders of an aggregate of 11,134,185 shares of the Company’s Stock at the close of business on May 31, 2018 were entitled to vote at the Annual Meeting, of which 6,965,966 shares were present in person or represented by proxy. At the Annual Meeting, the Company’s stockholders voted as follows:
Proposal One: The stockholders elected each of the following individuals as a director for a one year term expiring on the date of the Company’s 2019 Annual Meeting of Stockholders and until their successors have been duly elected and qualified.
| Name | For | Against | Withheld | Broker Non-Votes |
| Garo H. Armen | 6,669,831 | 188,080 | – | |
| Robert B. Stein | 6,669,835 | 188,076 | – | |
| Khalil Barrage | 6,669,842 | 188,069 | – | |
| Brian J. Corvese | 6,669,842 | 188,069 | – | |
| Josh Silverman | 6,669,843 | 188,068 | – |
Proposal Two: The stockholders ratified the selection of MaloneBailey LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.
| For | Against | Abstain |
| 6,777,691 | 188,162 |
Proposal Three: The stockholders approved, on an advisory basis, the 2017 compensation for the Company’s named executive officers, as described in the proxy statement for the 2018 Annual Meeting (the “Say-on-Pay Vote”).
| For | Against | Abstain | Broker Non-Votes |
| 6,348,275 | 213,198 | 296,438 | 108,055 |
Proposal Four: Advisory vote on the frequency of the Say-on-Pay Vote:
| 1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes |
| 662,244 | 25,012 | 5,774,227 | 396,428 | – |
3 years received the affirmative vote of a majority of the votes cast by stockholders entitled to vote.
About PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.
